GlaxoSmithKline Pakistan (KAR:GLAXO) Growth Rank: 8 (As of Aug. 18, 2026) — 11% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨345.21
GF Value ₨322.79
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Growth Rank?

GlaxoSmithKline Pakistan KAR:GLAXO +0.15% 93 Growth Rank is 8 as of Aug. 18, 2026, which is 11% below its 10-year median of 9.00. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨322.79 (Fairly Valued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pakistan has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

GlaxoSmithKline Pakistan Growth Rank Related Terms

KAR:GLAXO vs ZTS, UTHR, VTRS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pakistan Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Growth Rank distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Growth Rank falls into.


KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Growth Rank of 8 as of Aug. 18, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 11% below median its historical median of 9.00. Over the past decade, GlaxoSmithKline Pakistan's Growth Rank has ranged from 4.00 to 10.00.
Is GlaxoSmithKline Pakistan's Growth Rank too high?
GlaxoSmithKline Pakistan's current Growth Rank of 8 is 11% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Growth Rank compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Growth Rank of 8 can be compared against companies in the Drug Manufacturers industry. Historically, GlaxoSmithKline Pakistan's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Growth Rank is 8, which is 11% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨322.79, compared to a current price of ₨345.21 — trading 6.9% above its estimated fair value. The current Growth Rank is 8, which is 11% below median its 10-year median of 9.00. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Growth Rank is 8 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨345.21 is trading 6.9% above its estimated GF Value™ of ₨322.79. GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.

Key valuation signals for KAR:GLAXO:

  • Growth Rank: 8 (11% below median its 10-year median of 9.00)
  • GF Value™: ₨322.79 vs. price of ₨345.21 (6.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨345.21
Price
₨322.79
GF Value